Lucid Diagnostics

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lucid Diagnostics excels in Q4, eyes growth through precancer detection

Lucid Diagnostics (LUCD) demonstrated robust performance in Q4 2022, focusing on growth, financial stability, and strategic initiatives for precancer detection.
The company's strengths lie in strong revenue potential, innovative testing models, and a proactive approach to securing payer coverage and expanding its market reach.
While facing challenges in cash management and sales team tenure, Lucid Diagnostics has opportunities to drive growth through geographic expansion, high-risk group engagement, and data-driven payer strategies.

Lucid Diagnostics reports robust Q1 performance and growth opportunities

Lucid Diagnostics showed strong performance with increased tests and financial security in Q1 2023.
The company's focus on early precancer detection and large target market are key strengths.
Challenges include improving payment collections and securing in-network contracts.
Opportunities lie in expanding outreach efforts and engaging with payers for coverage.

Lucid Diagnostics reports robust Q2 performance and eyes sustained growth

Lucid Diagnostics delivered a strong Q2 performance with notable revenue growth and operational improvements.
While facing challenges in revenue recognition and payer engagement, the company's focus on clinical utility studies and high-volume events presents growth opportunities.
With a solid financial position and a strategic approach to market access, Lucid is poised for sustained growth and increased market penetration.

Lucid Diagnostics (LUCD) reports stellar Q3 growth and eyes market expansion

Lucid Diagnostics (LUCD) demonstrated strong performance in Q3 2023, marked by substantial revenue and test volume growth. The company's strategic initiatives, financial stability, and focus on market access position it for continued success. While challenges in managing expenses persist, Lucid's opportunities for expansion and engagement with key stakeholders pave the way for future growth and profitability.

Lucid Diagnostics reports stellar Q4 results and eyes market expansion

Lucid Diagnostics (LUCD) showcased robust financial performance and strategic initiatives in Q4 2023, driving revenue growth and market expansion.
While facing challenges such as significant operating expenses and uncertainties in reimbursement processes, Lucid is well-positioned to capitalize on opportunities for revenue realization and market access.
With a focus on clinical validity, engagement with payers, and exclusive product rights, Lucid demonstrates a strong competitive advantage and potential for sustained growth in the diagnostic market.

Lucid Diagnostics excels in Q1 2024, poised for market expansion

Lucid Diagnostics delivered strong financial performance in Q1 2024, showcasing revenue growth, robust margins, and a strengthened balance sheet.
The company's focus on market access strategies, innovative diagnostics, and revenue cycle improvements positions them for future success.
While facing challenges such as pending adjudications and international expansion limitations, Lucid is well-positioned to capitalize on opportunities in healthcare partnerships and market awareness.
Overall, Lucid's commitment to driving commercial potential and enhancing cancer detection technologies underpins their growth trajectory and shareholder value creation.

Lucid Diagnostics reports robust revenue growth and navigates reimbursement challenges

Lucid Diagnostics demonstrated strong revenue growth momentum driven by record test volumes and positive clinical data.
While facing reimbursement challenges, the company's proactive approach to market access and partnerships positions them for future success.
Maintaining a healthy cash position and focusing on operational efficiency are key strengths that support Lucid's growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

PAVmed

Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard® Esophageal DNA test  as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy (EGD) for detection of esophageal precancer (Barrett's Esophagus or BE) and cancer. The manuscript entitled Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard® Triage , is currently available on the leading health sciences preprint server, MedRxiv, while undergoing peer review for publication.

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

NEW YORK , Aug. 5, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Dates: August 12-13, 2024 Canaccord Genuity 44th Annual Growth Conference Fireside Chat: Tuesday, August 13, 2024, at 1:30 PM ET The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, August 12, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

BlackSky Technology

Porch Group

Hypergrowth stocks isn't so much about returns as it is time. Don't get me wrong: when you think about the words “hyper” and “growth,” the price moving in the northward direction along the y-axis is crucial.

3 Hypergrowth Stocks That Speculators Should Keep Tabs On

Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter.

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com. "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experience with easily accessible, informative content on Lucid and its innovative technologies," said Jenna Mowatt, Vice President of Marketing and Communications at Lucid Diagnostics.

Lucid Diagnostics Launches New Corporate Website

Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.

Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data

Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed publication Studies further strengthen EsoGuard's clinical validity data in support of upcoming Medicare LCD pre-submission meeting and ongoing commercial payor engagements NEW YORK , July 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard® Esophageal DNA test on samples collected with the EsoCheck® Esophageal Cell Collection Device for detection of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) in a screening population. This is the second clinical validation study in a screening population following previously announced positive data from the Cleveland VA screening study, which was recently accepted for peer-reviewed publication.

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event to ensure its at-risk firefighters could be tested for esophageal precancer.

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

Aeva Technologies Inc

Ovid Therapeutics

No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024

Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Tuesday, May 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and First Quarter 2024 Financial Results

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Mike Matson - Needham Anthony Vendetti - Maxim Group Vidyun Bais - BTIG Kyle Mikson - Canaccord Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics First Quarter 2024 Business Update Conference Call. At this time all lines are in listen only mode.

Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript

Quarterly EsoGuard® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for July 17, 2024 Conference call and webcast to be held today, May 13 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Monday, May 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection NEW YORK , May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies. EsophaCap is not a commercial Lucid product.

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK , May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication further strengthens EsoGuard's clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device . This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

NEW YORK , April 29, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the tragic death of her husband of esophageal cancer.

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Augmedix

Stereotaxis Inc

Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.

3 Penny Stocks That Could Make a Big Comeback by the End of Q2

NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T. The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here.

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript

Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage Conference call and webcast to be held tomorrow, March 26 th at 8:30 AM ET NEW YORK , March 25, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the year ended December 31, 2023. Conference Call and Webcast The webcast will take place on March 26, 2024, at 8:30 AM, and be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard is a "powerful screening tool" for esophageal precancer and cancer NEW YORK , March 21, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that investigators at the Louis Stokes Cleveland Veterans Affairs Medical Center, led by Katarina B. Greer, M.D.

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK , March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024—the world's premier meeting for digestive disease professionals. "We are excited that our technologies will be prominently featured in multiple presentations at this year's DDW conference," said Suman Verma, M.D.

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

News for Lucid Diagnostics Stock (LUCD)